Targeting PI3K in CDK4/6-resistant breast cancer cells appears to be effective in both PIK3CA mutant and wild-type models, whereas targeting mTORC1 is effective in PIK3CA wild-type xenograft and one of two PIK3CA-mutant models. This evidence concerns the gene CDK4 and breast carcinoma.